RBB 001

Drug Profile

RBB 001

Alternative Names: Fv-Hsp70; Fv-Hsp70 Cardiovasular - Rubicon Biotechnology; Fv-Hsp70 Defense Countermeasures - Rubicon Biotechnology; RBB001

Latest Information Update: 12 Aug 2016

Price : $50

At a glance

  • Originator Rubicon Biotechnology
  • Class Heat shock proteins; Recombinant fusion proteins
  • Mechanism of Action Apoptosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Myocardial infarction; Stroke
  • Research Poisoning

Most Recent Events

  • 12 Aug 2016 Early research in Poisoning in USA (Inhalation)
  • 12 Aug 2016 Preclinical trials in Myocardial infarction in USA (Parenteral)
  • 12 Aug 2016 Preclinical trials in Stroke in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top